Evidence map›Paper›PMID 36925720›Full record

ArticleiScience2023

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron.

Jakob Kreye, S Momsen Reincke, Stefan Edelburg, Lara M Jeworowski, Hans-Christian Kornau, Jakob Trimpert, Peter Hombach, Sophia Halbe, Volker Nölle, Martin Meyer and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 1 country.

Jakob KreyeGerman Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany.
S Momsen ReinckeGerman Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany.
Stefan EdelburgMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Lara M JeworowskiInstitute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Hans-Christian KornauGerman Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany.
Jakob TrimpertInstitute of Virology, Freie Universität Berlin, 14163 Berlin, Germany.
Peter HombachMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Sophia HalbeMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Volker NölleMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Martin MeyerMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Stefanie KattenbachMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Elisa Sánchez-SendinGerman Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany.
Marie L SchmidtInstitute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Tatjana SchwarzInstitute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Ruben RoseInstitute for Infection Medicine, Christian-Albrechts-Universität zu Kiel and University Medical Center Schleswig-Holstein, 24105 Kiel, Germany.
Andi KrumbholzInstitute for Infection Medicine, Christian-Albrechts-Universität zu Kiel and University Medical Center Schleswig-Holstein, 24105 Kiel, Germany.
Sophie MerzIDEXX Laboratories, 70806 Kornwestheim, Germany.
Julia M AdlerInstitute of Virology, Freie Universität Berlin, 14163 Berlin, Germany.
Kathrin EschkeInstitute of Virology, Freie Universität Berlin, 14163 Berlin, Germany.
Azza AbdelgawadInstitute of Virology, Freie Universität Berlin, 14163 Berlin, Germany.
Dietmar SchmitzGerman Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany.
Leif E SanderDepartment of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, 10117 Berlin, Germany.
Uwe JanssenMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Victor M CormanBerlin Institute of Health at Charité, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.
Harald PrüssGerman Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany.
Miltenyi Biotec (Germany) · DEGerman Center for Neurodegenerative Diseases · DEHumboldt-Universität zu Berlin · DEFreie Universität Berlin · DEChristian-Albrechts-Universität zu Kiel · DEIDEXX Laboratories (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recurrent emerging of novel viral variants of concern (VOCs) with evasion of preexisting antibody immunity upholds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case numbers and maintains a persistent demand for updated therapies. We selected the patient-derived antibody CV38-142 based on its potency and breadth against the VOCs Alpha, Beta, Gamma, and Delta for preclinical development into a therapeutic. CV38-142 showed

Indexed as

ImmunologyVirology

Identifiers

PMID36925720
PMCPMC9979625
OpenAlexW4322766855

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.